Targeting the NF-[kappa]B Pathway as a Combination Therapy for Advanced Thyroid Cancer

• Published in: PloS one 2015-08, Vol.10 (8)
• Main Authors: Pozdeyev, Nikita, Berlinberg, Adam, Zhou, Qiong, Wuensch, Kelsey, Shibata, Hiroyuki, Wood, William M, Haugen, Bryan R
• Format: Article
• Language: English
• Subjects: Analysis; Apoptosis; Chemotherapy; Docetaxel; Health aspects; Ionizing radiation; Thyroid cancer
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0134901

NF-[kappa]B signaling plays an important role in tumor cell proliferation, cell survival, angiogenesis, invasion, metastasis and drug/radiation resistance. Combination therapy involving NF-[kappa]B pathway inhibition is an attractive strategy for the treatment of advanced forms of thyroid cancer. This study was designed to test the efficacy of NF-[kappa]B pathway inhibition in combination with cytotoxic chemotherapy, using docetaxel and ionizing radiation in in vitro models of thyroid cancer. We found that while both docetaxel and ionizing radiation activated NF-[kappa]B signaling in thyroid cancer cells, there was no synergistic effect on cell proliferation and/or programmed cell death with either genetic (transduction of a dominant negative mutant form of I[kappa]B[alpha]) or pharmacologic (proteasome inhibitor bortezomib and IKK[beta] inhibitor GO-Y030) inhibition of the NF-[kappa]B pathway in thyroid cancer cell lines BCPAP, 8505C, THJ16T and SW1736. Docetaxel plus bortezomib synergistically decreased in vitro invasion of 8505C cells, but not in the other cell lines. Screening of a panel of clinically relevant targeted therapies for synergy with genetic NF-[kappa]B inhibition in a proliferation/cytotoxicity assay identified the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) as a potential candidate. However, the synergistic effect was confirmed only in the BCPAP cells. These results indicate that NF-[kappa]B inhibitors are unlikely to be beneficial as combination therapy with taxane cytotoxic chemotherapy, external radiation therapy or radioiodine therapy. There may be unique circumstances where NF-[kappa]B inhibitors may be considered in combination with docetaxel to reduce tumor invasion or in combination with HDAC inhibitors to reduce tumor growth, but this does not appear to be a combination therapy that could be broadly applied to patients with advanced thyroid cancer. Further research may identify which subsets of patients/tumors may respond to this therapeutic approach.